Mark Cepela, MD
Ophthalmology · Crestview Hills, KYNPI 1730181009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Amgen at 31.4% of the total. Reporting peaked in 2024 at $745 and has fallen 52.9% since, to $351 in 2025.
Across 54 payments — averaging $50.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$860
- AbbVie$444
- Merz North America, Inc.$389
- Biotissue Holdings Inc.$373
- Halozyme Inc$174
- Harrow Eye, LLC$150
- plus $348 from 5 others
What the payments were for
- Food & beverage$2,70399%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 24 | $860 |
| AbbVie(2 entities) | 4 | $444 |
| Merz North America, Inc. | 5 | $389 |
| Biotissue Holdings Inc. | 4 | $373 |
| Halozyme Inc | 10 | $174 |
| Harrow Eye, LLC | 1 | $150 |
| Galderma Laboratories, L.p. | 2 | $122 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $99 |
| Ocular Therapeutix, Inc. | 1 | $84 |
| Astellas Pharma US Inc | 1 | $23 |
| Glaukos Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,738 in reported general payments places this provider in the 65th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 50 | $522 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 58 | $334 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 13 | $150 |
| ValacyclovirValacyclovir Hcl | 24 | $112 |
| Azithromycin | 24 | $70 |
| Prednisone | 14 | $16 |
| Diazepam | 14 | $11 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Crestview Hills
- Saif JaweedCrestview Hills$12K
- Aaron NollCrestview Hills$9K
- Jean NollCrestview Hills$5K
- Matthew DykhuizenCrestview Hills$4K
- Edward HollandEdgewood$678K
- Gary WortzLexington$159K
- Jeremy ClarkLouisville$131K
- Bruce KofflerLexington$49K
- Guruprasad PattarLouisville$36K
- Jeffery TaylorPaducah$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.